---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: HELP"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: HELP. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 14 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence/help"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: HELP

<a id="heading-3.1.6"></a>

## 3.1.6 HELP

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Prevention objective

> “preventing hereditary angioedema attacks.”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Study sites

> “41 sites”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Parallel-group design

> “randomized, double-blind, parallel-group, placebo-controlled”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Age eligibility

> “Patients aged ≥ 12 years”

Source: [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Subcutaneous lanadelumab regimens; placebo comparator

| Regimen | Dose and interval |
| --- | --- |
| Lower-dose monthly | “150 mg q4wks” |
| Higher-dose monthly | “300 mg q4wks” |
| Every two weeks | “300 mg q2wks” |

Source: [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Primary clinical endpoint

> “number of investigator-confirmed attacks of hereditary angioedema”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Randomized treatment groups

| Group | Participants |
| --- | --- |
| Lanadelumab 150 mg every four weeks | “28” |
| Lanadelumab 300 mg every four weeks | “29” |
| Lanadelumab 300 mg every two weeks | “27” |
| Placebo | “41” |

Source: [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Primary analysis population and model

> “Intent-to-Treat”
> “Poisson regression model”

Source: [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

##### Study completion

| Disposition | Participants, n (%) |
| --- | --- |
| Completed | “113 (90.4%)” |

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

##### Age at baseline

| Characteristic | Reported value |
| --- | --- |
| Mean age, years | “40.7” |

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Mean monthly attack rate over 26 weeks

| Treatment | Attacks per month |
| --- | --- |
| Lanadelumab 150 mg every four weeks | “0.48” |
| Lanadelumab 300 mg every four weeks | “0.53” |
| Lanadelumab 300 mg every two weeks | “0.26” |
| Placebo | “1.97” |

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

##### Participants achieving the AE-QoL minimal clinically important difference

| Population | Proportion |
| --- | --- |
| All lanadelumab regimens pooled | “70%” |
| Placebo | “37%” |
| Lanadelumab 300 mg every two weeks | “81%” |

Source: [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Injection-site reactions

| Treatment | Participants, n (%) |
| --- | --- |
| Lanadelumab 150 mg every four weeks, n=28 | “16 (57)” |
| Lanadelumab 300 mg every four weeks, n=29 | “13 (45)” |
| Lanadelumab 300 mg every two weeks, n=27 | “15 (56)” |
| Placebo, n=41 | “14 (34)” |

Source: [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary

The trial randomized 125 participants to three lanadelumab regimens (28, 29, and 27 participants) or placebo (41 participants), and 113 (90.4%) completed the study. The primary analysis used the “Intent-to-Treat” population and a “Poisson regression model”. Because three active regimens shared the randomization, each lanadelumab group contained 27 to 29 participants, which limits precision for comparisons between regimens and for uncommon adverse events; injection-site reactions were reported in 45% to 57% of lanadelumab groups and in 34% of the placebo group. The placebo-controlled period does not describe outcomes over longer treatment. Lanadelumab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/); [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680); [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
